The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
REGULATORY
Japan Expects COVID Vaccine Supply of 32 Million Doses from 5 Makers in 2024-25
The Japanese government is anticipating a COVID-19 vaccine supply of roughly 32.24 million doses in the 2024/2025 fall-winter season, with updated shots for the JN.1 strains expected to be provided from five manufacturers including ones under regulatory review. The Ministry…
To read the full story
Related Article
- Japan Expects COVID Vaccine Supply of 9 Million Doses in 2025-26
September 1, 2025
- MHLW Lays Out Procedures for Transition to Trivalent Flu Shots
February 17, 2025
- Daiichi Sankyo Releases JN.1-Tailored COVID Jab Daichirona
September 25, 2024
- Japan Panel OKs 5 COVID Vaccines for NIP Use from October
September 20, 2024
- Pfizer to Roll Out JN.1-Adapted COVID Vaccine
September 19, 2024
- JN.1-Targeting Nuvaxovid Approved in Japan: Takeda
September 6, 2024
- Daiichi Sankyo Wins Japan Approval for Updated COVID Jab for JN.1
September 5, 2024
- Pfizer Earns Japan Nod for JN.1-Adapted COVID Vaccine
August 9, 2024
- Japan’s Fall-Winter COVID Vaccinations Likely to Start from October
July 23, 2024
- Moderna Files Updated Spikevax for JN.1 Strain in Japan
June 11, 2024
- Novavax COVID Vaccine to Be Adapted to JN.1 Strain: Takeda
June 10, 2024
- Japan Selects JN.1 for COVID-19 Vaccine Formula in 2024-2025 Season
May 30, 2024
REGULATORY
- MHLW to Set Up Expert Panel on Using Disease Registries in Drug Development
January 13, 2026
- Chuikyo Moves to Allow Special Mixed-Billing for Santen’s Myopia Drug
January 13, 2026
- Japan Panel to Review AbbVie’s Aquipta, Ipsen’s Sohonos on January 23
January 13, 2026
- MHLW Pharma Director Says Uniform Drug Price Hike “Not Realistic,” Targeted Support Preferred
January 9, 2026
- MHLW Issues Guidance on Revised PMD Act Ahead of May Enforcement
January 6, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…